Tests how glucagon affects fasting blood sugar and insulin in prediabetes
Tests glucagon's effect on fasting blood sugar in adults with prediabetes.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Rochester, United StatesSee the site
- Trial code
- Registry title
- Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 1 Apr 2025
- Expected to end
- 1 Jul 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Glucagon
- Glucose
- Record updated
- 20 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 25 to 65 with normal or slightly raised fasting blood sugar and normal or impaired glucose tolerance. It studies how glucagon affects insulin and glucose.
- Age
- 25 Years to 65 Years
- Sex
- All sexes can join.
- Disease stage
- Normal or impaired fasting glucose and normal or impaired glucose tolerance (prediabetes range).
- Earlier treatment
- People who use any glucose-lowering medicine, including metformin or sulfonylureas, cannot join. Prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty or vagotomy is also not allowed.
Main reasons for not taking part
- HbA1c less than 6.5% (48 mmol/mol)
- Use of any glucose-lowering medicine, including metformin or sulfonylureas
- Positive pregnancy test at enrollment or during the study
- Prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty or vagotomy
- Active systemic illness or malignancy
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Individuals with normal or impaired fasting glucose and normal or impaired glucose tolerance
Who cannot take part
- History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy
- Active systemic illness or malignancy
- Symptomatic macrovascular or microvascular disease
- HbA1c less than 6.5%
- Use of any glucose-lowering agents including metformin or sulfonylureas
- For female subjects: positive pregnancy test at the time of enrollment or study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 65 years old?
Where in United States
- Mayo Clinic in RochesterRochester, United StatesContact: Kim Osmundson, CCRPTaking people
About the trial
What the trial wants to find out
Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes. However, little is known about the regulation of glucose concentrations in the fasting state relative to what is known about the postprandial state. The proposed experiment is part of a series of experiments designed to establish how glucagon and insulin interact with their receptors to control fasting glucose in health and in prediabetes.
The 2 groups in the trial
- Glucagon InfusionExisting treatment, for comparison
A glucagon infusion (0.2 ng/kg/min) will start at 0900 (0 min), increasing to 0.4 (1000), 0.6 (1100) and 0.8 ng/kg/min (1200) at 60-minute intervals - ending at 1300 (240 min).
Treatment: Glucagon
- Glucose InfusionPlacebo, for comparison
At 0900 (0 min) a glucose infusion will commence, and the infusion rate varied to replicate (± 5mg/dL) that individual's glucose concentrations observed during the Glucagon Infusion Day. The experiment will end at 1300 (240 min) when infusions are stopped.
Treatment: Glucose
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes
- Plain-language title
- Tests how glucagon affects fasting blood sugar and insulin in prediabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06424106, who can take part
- Record updated
- 20 April 2026